Sp427
GUT MICROBIOME AS A DETERMINANT OF TREATMENT RESPONSE IN IBD
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
In this session, you will learn about the advances in microbial biotransformation of drugs and this can impact clinical outcomes and adverse events.
In this session, you will learn about the advances in microbial biotransformation of drugs and this can impact clinical outcomes and adverse events.
Presenter
Tracks
Related Products
INTERACTIONS BETWEEN HOST DIETARY INTAKE AND GUT MICROBIAL TRANSCRIPTION IN INFLAMMATORY BOWEL DISEASE
The microbiome plays a central role in intestinal inflammation in IBD. It is influenced by environmental factors included diet…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
AN EMPIRICAL DIETARY PATTERN ASSOCIATED WITH GUT MICROBIAL FEATURES IN RELATION TO COLORECTAL CANCER RISK
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
